Illumina (ILMN) Q2 FY26 earnings call

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Jul 30, 2026

Source: earnings call transcript

Illumina delivered a strong Q2 FY26, driven by robust demand from clinical customers and continued high NovaSeq X placements, leading to raised full-year revenue and EPS guidance. The company is expanding its multiomics portfolio and seeing early traction with BioInsight, while navigating persistent caution in research markets and managing inflationary cost pressures. Management remains confident in achieving high single-digit revenue growth in 2027, supported by the expanding NovaSeq X installed base.

You’re reading a preview. Opening the full call uses 1 concall credit.

ILMN operating KPIs by quarter

ILMN operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Dec 2024 Q4 FY24	Mar 2025 Q1 FY25	Sep 2025 Q3 FY25	This call Jun 2026 Q2 FY26	Change vs prior quarter
NovaSeq X placements	91 We placed 91 instruments during the quarter, bringing the installed base to 630. Source: earnings call transcript	60+ Our NovaSeq X instruments continue to perform well, exceeding our expectations with another quarter of over 60 placements in Q1, following more than 90 placements in Q4. Source: earnings call transcript	55+ In Q3, we had another strong quarter for the NovaSeq X with more than 55 instruments placed in line with our goal of 50 to 60 placements per quarter. Source: earnings call transcript	95+ Rest of World organic revenue grew 8.1%, above the high end of our guidance and demand for NovaSeq X remained high more than 3 years after launch with more than 95 placements in the quarter. Source: earnings call transcript	—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.